AAD: New Results From Sanofi's Amlitelimab Phase 3 Studies in Atopic Dermatitis Presented in Late-breaking Research Session
March 28, 2026
March 28, 2026
PARIS, France, March 28 -- Sanofi, a life sciences company, issued the following news release:
* * *
AAD: new results from Sanofi's amlitelimab phase 3 studies in atopic dermatitis presented in late-breaking research session
* Across the COAST 1, COAST 2, and SHORE phase 3 studies, amlitelimab, dosed either Q4W or Q12W, showed progressively increasing efficacy, with no evidence of plateau at Week 24 across endpoints
* Data reinforce potent . . .
* * *
AAD: new results from Sanofi's amlitelimab phase 3 studies in atopic dermatitis presented in late-breaking research session
* Across the COAST 1, COAST 2, and SHORE phase 3 studies, amlitelimab, dosed either Q4W or Q12W, showed progressively increasing efficacy, with no evidence of plateau at Week 24 across endpoints
* Data reinforce potent . . .